Drugs / Ulinastatin
Ulinastatin
also known as
UTI · urinary trypsin inhibitor · AER002 · Bikunin · Estotin · Mingin · Miraclid · Trypsin inhibitor uti-1 · +7 more
Trials 25 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04393311 | Feb → Aug 2022 | COVID-19 | Stanford University | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05877508 | Aug 2023 → Jul 2024 overdue | long COVID-19 | Michael Peluso, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02895191 | Aug 2016 → Sep 2019 | acute respiratory distress syndrome | Techpool Bio-Pharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT01287806 | Feb 2011 → Dec 2012 | — | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01865266 | Jan 2014 → Dec 2015 | pneumonia caused by pseudomonas aeruginosa infection | Shanghai Minhang Central Hospital | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05391789 | Jul 2022 → Jun 2023 | infectious disease with sepsis | Huashan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03387774 | Jan 2018 → Dec 2021 | mucositis | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT05895240 | May → Oct 2023 | infectious disease with sepsis, multiple organ dysfunction syndrome | Jinnah Postgraduate Medical Centre | Unknown | No outcome recorded |
| Phase 4 | NCT02647554 | Dec 2016 → May 2021 | infectious disease with sepsis | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03154814 | Jan 2016 → Apr 2017 | cardiac valvular defect | Konkuk University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02527811 | Apr 2015 → Jun 2018 | congenital heart disease | Techpool Bio-Pharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT01132521 | Jun 2010 → Dec 2018 | acute pancreatitis | Techpool Bio-Pharma Co., Ltd. | Suspended | No outcome recorded |
| Phase 4 | NCT01084044 | Jan 2010 → May 2011 | coronary artery disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT00944385 | Jun 2009 → Apr 2011 | aortic valve disorder | Yonsei University | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07382375 | Dec 2027 expected | aortic disorder | Nanjing Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07672496 | Oct 2026 → Dec 2027 expected | immunodeficiency disease, infectious disease with sepsis | Fujian Medical University Union Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05716256 | Feb → Jun 2023 | — | Huazhong University of Science and Technology | Completed | No outcome recorded |
| — | NCT05534802 | Sep 2022 → Dec 2024 | — | Qin Zhang | Completed | No outcome recorded |
| — | NCT04711889 | Jan 2021 → Jun 2022 | aortic disorder | Nanjing Medical University | Completed | No outcome recorded |
| — | NCT04028024 | Aug 2019 → Dec 2020 | — | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| — | NCT03089957 | Feb 2017 → Dec 2020 | acute respiratory distress syndrome | Peking University Third Hospital | Completed | No outcome recorded |
| — | NCT02258906 | Oct 2014 → Jul 2016 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT01894334 | Apr 2013 → Jan 2015 | aortic disorder | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| — | NCT01643447 | May 2012 → Dec 2014 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Completed | No outcome recorded |
| — | NCT01060189 | Apr 2008 → Jan 2009 | vascular hemostatic disease | Chinese Academy of Medical Sciences, Fuwai Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT01518569 Comparator | Mar → Jun 2008 | cardiovascular disorder | Konkuk University Medical Center | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07520370 Comparator | Jun 2026 → Dec 2029 expected | brain neoplasm, stroke disorder | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06966687 Comparator | Apr 2025 → Dec 2026 expected | aortic aneurysm | Nanjing Medical University | Enrolling by invitation | No outcome recorded |
| — | NCT04473144 Comparator | Aug 2020 → Jul 2021 | acute kidney injury | Ajou University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ulinastatin | “Ulinastatin (Techpool inc,Guangdong,China) was administered to the group as a bolus of 100,000 U diluted in 100 mL of normal saline every 8 hour.” NCT01865266 ↗27 |
| Known as | AER002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05877508 ↗ |
| Known as | Bikunin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108163 ↗ |
| Known as | Estotin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108163 ↗ |
| Known as | Mingin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108163 ↗ |
| Known as | Miraclid | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108163 ↗ |
| Known as | Trypsin inhibitor uti-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108163 ↗ |
| Known as | Ulinastatina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108163 ↗ |
| Known as | Ulinastatine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108163 ↗ |
| Known as | Ulistine | “Urinary trypsin inhibitor, ulistine, has anti-inflammatory and antioxidant effects, so it has been reported to protect against renal ischemia/reperfusion injury.” NCT04473144 ↗ |
| Known as | urinary trypsin inhibitor | “Ulinastatin, urinary trypsin inhibitor(UTI), is a secreted Kunitz-type protease inhibitor with a wide inhibition spectrum, including plasmin.” NCT01060189 ↗1“Ulinastatin, a urinary trypsin inhibitor, is considered as a potentially beneficial immunomodulator drug for MODS.” PMID 26565549 ↗ Mar 2016 |
| Known as | Urinary trypsin inhibitor 1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108163 ↗ |
| Known as | Urinastatin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108163 ↗ |
| Known as | urine trypsin inhibitor | “Ulinastatin, a urine trypsin inhibitor, relieves systemic inflammation and improves coagulation profiles with however sparse evidence of its effects on blood loss and...” PMID 32410683 ↗ May 2020 |
| Known as | Uristatin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108163 ↗ |
| Known as | UTI | “Ulinastatin, urinary trypsin inhibitor(UTI), is a secreted Kunitz-type protease inhibitor with a wide inhibition spectrum, including plasmin.” NCT01060189 ↗2“Ulinastatin (UTI) is a glycoprotein that exists in human blood and can be isolated and purified from human urine.” NCT05391789 ↗ “Ulinastatin (UTI): ulinastatin was intravenous drip at a dose of one hundred thousand units added” NCT03387774 ↗ |
| Action | Inhibit | “with a wide inhibition spectrum, including plasmin” NCT01060189 ↗ |
| Modality | Protein / enzyme biologic | “Ulinastatin, urinary trypsin inhibitor(UTI), is a secreted Kunitz-type protease inhibitor” NCT01060189 ↗ |
| Route | Intravenous | “intravenously infused for 1-2h” NCT01132521 ↗ |